Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme (SEJ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03047473
Recruitment Status : Recruiting
First Posted : February 9, 2017
Last Update Posted : February 6, 2019
Sponsor:
Information provided by (Responsible Party):
Dr. Francois Jacques, Clinique Neuro-Outaouais

Brief Summary:

This is a safety and tolerability study looking at the addition of avelumab, an immune checkpoint inhibitor, to standard therapy of temozolomide and radiotherapy in patients with newly diagnosed glioblastoma multiforme.

All patients will be receiving active therapy. Patients will begin the avelumab within 3 weeks of finishing their radiotherapy. Avelumab will be given at a dose of 10mg/kg IV every 2 weeks concomitantly with the monthly temozolomide. Avelumab will be continued for a total of 52 weeks.


Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme of Brain Biological: avelumab Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Intervention Model Description: single center, add on, open label, single dose, single arm
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
Actual Study Start Date : March 10, 2017
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Avelumab

Arm Intervention/treatment
Experimental: Newly diagnosed GBM
single arm, open label Addition of Avelumab to standard treatment
Biological: avelumab
add on of avelumab 10mg/kg IV to standard therapy




Primary Outcome Measures :
  1. Safety and tolerability according to emergent adverse event leading to avelumab interruption or termination [ Time Frame: over the course of the 52 weeks stsudy ]

    Safety and tolerability based on avelumab related adverse events leading to permanent or transient discontinuation of avelumab Treatment related adverse events of special interest will include those of autoimmune origin (irAE).

    The adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0



Secondary Outcome Measures :
  1. iRANO criteria [ Time Frame: over the course of the 52 weeks study ]
    Radiological tumor response will be graded according to the Immunotherapy Response Assessment for Neuro-Oncology (iRANO) criteria by a single study radiologist based on the gadolinium enhanced brain MRI performed at the study center at baseline and at the final visit (week 52) or within 2 weeks of the end of avelumab treatment visit and evaluations of locally obtained MRI's Clinical tumor response as per the iRANO criteria will be evaluated by the principal investigator based on the protocol specified neurological exams The OS and PFS will be stratified according to MGMT status, baseline age (>50yrs), baseline Karnofsky performance score (score of 100), whether the patient had a radical tumor resection vs biopsy and according to histopathological diagnosis of primary versus secondary GBM


Other Outcome Measures:
  1. potential biomarkers of response [ Time Frame: over the course of the 52 weeks study ]

    The correlation between OS and PFS and the prevalence of PD-L1 expression on tumor cells and microglia/macrophages within the tumor, the histological immunoscore.

    The correlation between OS and PFS in relation the baseline corticosteroid dose, the average daily corticosteroid dose over the whole study duration, inability because of temozolomide related tolerability issues to complete the 6 month temozolomide cycles, the change from baseline to end of study neurocognitive function as measured by the evoked potential P300 and the incidence and severity of irAE's.

    The change between baseline biomarker results and those obtained from biomarkers in tissue samples from patients with second surgical resection ie treatment failures




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed informed consent.
  2. Age ≥ 18 years.
  3. Present with newly diagnosed supratentorial Glioblastoma (GBM) with a tissue diagnosis that has been established following either a surgical resection or biopsy. This includes treatment-naïve -(chemotherapy and radiotherapy)- patients with prior diagnosis of a lower grade astrocytoma that has been upgraded to a histologically verified GBM.
  4. Karnofsky performance score of 70 or higher.
  5. Patients entering the study must be on a stable dose of up to 12 mg (maximum) of Dexamethasone (or equivalent) daily for symptoms related to cerebral edema. Following the first dose of avelumab, the duration of treatment with the current dose of dexamethasone (maximum 12 mg/day) or equivalent, should be no more than 7 consecutive days. The investigator(s) should make every effort to taper the dexamethasone as soon as symptom improvement allows to the lowest tolerable dose that controls the CNS symptoms.
  6. Will be or is undergoing or has received the standard therapy of chemo radiation therapy (60Gy in 30 fractions of 2Gy/day with concurrent temozolomide of 75mg/m2 per day PO) no more than 21 days ago.
  7. Has not yet begun but will begin standard monthly temozolomide therapy.
  8. Patient must have at least 1 formalin fixed paraffin embedded tumor tissue block representative of glioblastoma available for biomarker analysis and determination of MGMT status (if not already done). If tumor block is not available or not of adequate quality, sufficient pathology material, representative of glioblastoma, must be available.
  9. Adequate hematological function defined by absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L, and hemoglobin ≥ 9 g/dL (may have been transfused).
  10. Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range and AST and ALT levels ≤ 2.5 × ULN for all subjects.
  11. Adequate renal function defined by an estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method).
  12. Negative serum pregnancy test at screening for women of childbearing potential.
  13. Highly effective contraception for both male and female subjects if the risk of conception exists. (Note: The effects of the trial drug on the developing human fetus are unknown; thus, women of childbearing potential and men able to father a child must agree to use 2 highly effective contraception, defined as methods with a failure rate of less than 1 % per year. Highly effective contraception is required at least 28 days prior, throughout and for at least 60 days after avelumab treatment.
  14. International normalized ratio (INR) or PT (secs) and activated partial thromboplastin time (aPTT):

    • in the absence of therapeutic intent to anticoagulate the subject: INR≤1.5 or PT ≤1.5 x ULN and aPTT ≤1.5 x ULN
    • in the presence of therapeutic intent to anticoagulate the subject: INR or PT and aPTT within therapeutic limits (according to the medical standard in the institution).

    NOTE: Use of full-dose anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose of anticoagulants for at least two weeks prior to randomization.

  15. Willing and able to comply with the protocol as judged by the Investigator

Exclusion Criteria:

  1. Patients who have evidence of leptomeningeal disease.
  2. Known significant pulmonary, cardiovascular, hepatic disorders or any other disease that in the opinion of the investigator would be contraindicated to receive anti PD-L1 therapy such as avelumab.
  3. Prior treatment with bevacizumab or any checkpoint immune blockade thérapies.
  4. Any other concomitant immunosuppressant other than temozolamide and steroids or any recent (within 3 months) experimental therapy.
  5. Patients who have finished their radiotherapy course more than 3 weeks prior to Baseline.
  6. Prior organ transplantation, including allogeneic stem cell transplantation.
  7. Significant acute or chronic infections including, among others:

    • Known history of testing positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
    • Positive test for HBV surface antigen and / or confirmatory HCV RNA (if anti-HCV antibody tested positive).
  8. Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent:

    • Subjects with diabetes type I, vitiligo, psoriasis, hypo or hyperthyroid disease or any other autoimmune disease not requiring immunosuppressive treatment are at the investigator's discretion eligible
    • Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses ≤ 10 mg or 10 mg equivalent prednisone per day
    • Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptable.
  9. Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI CTCAE v 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma).
  10. Pregnancy or lactation.
  11. Known alcohol or drug abuse.
  12. Any psychiatric or cognitive condition that would prohibit the understanding or rendering of informed consent.
  13. Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines.
  14. Contraindication or intolerance to temozolomide.
  15. Any other malignancy within 5 years prior to randomization, except for adequately controlled limited basal cell carcinoma of the skin, squamous carcinoma of the skin or carcinoma in situ of the cervix.
  16. Evidence of any active infection requiring hospitalization or IV antibiotics within 2 weeks prior to randomization.
  17. Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.
  18. Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03047473


Contacts
Layout table for location contacts
Contact: Francois Jacques, MD 819-777-2500 francois.jacques@neuro-outaouais.ca
Contact: Victorine Sikati Foko 819-777-2500 ext 211 victorine.sikatifoko@neuro-outaouais.ca

Locations
Layout table for location information
Canada, Quebec
Clinique Neuro-Outaouais Recruiting
Gatineau, Quebec, Canada, J8Y 1W2
Contact: Victorine Sikati-Foko, RN Msc    819-777-2500 ext 3    victorine.sikatifoko@neuro-outaouais.ca   
Sponsors and Collaborators
Clinique Neuro-Outaouais
Investigators
Layout table for investigator information
Principal Investigator: François Jacques, MD Clinique Neuro-Outaouais

Additional Information:
Layout table for additonal information
Responsible Party: Dr. Francois Jacques, neurologist, Clinique Neuro-Outaouais
ClinicalTrials.gov Identifier: NCT03047473     History of Changes
Other Study ID Numbers: CNO-006
First Posted: February 9, 2017    Key Record Dates
Last Update Posted: February 6, 2019
Last Verified: July 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Dr. Francois Jacques, Clinique Neuro-Outaouais:
newly diagnosed

Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs